amfAR, The Foundation for AIDS Research
amfAR’s public policy office in Washington, D.C., educates policy makers, the media, and the public about evidence-based policies to address HIV/AIDS in the U.S. and around the world.
amfAR report spells out recommendations for health plans and health care purchasers
Investing in HIV/AIDS Research Could Fund the World’s Next Medical Breakthrough
Assessing the state of harm reduction interventions to prevent and treat HIV among people who inject drugs worldwide
New database enables users to access and understand PEPFAR programs and priorities at a deeper level than was previously possible.
Over 3 million Americans have hepatitis C virus (HCV), and an estimated 75% are undiagnosed. But the CDC’s HCV surveillance system is seriously underfunded.
amfAR’s issue briefs and short films make a convincing case for ending the ban on federal funding for syringe services programs.
Assessment of the
Use of Key Populations
Data in Domestic
Budgeting Practices in
Kenya and South Africa
A research team at amfAR recently evaluated the
extent to which funds from the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) were allocated to programs targeting Key Populations in proportion to their epidemic burden.
The number of Americans (3.2 million) living with chronic Hepatitis C Virus (HCV) is nearly five times the population of Washington, DC
Syringe services programs (SSPs) are proven to be a highly effective—and cost-effective—method of infectious disease prevention.
© 2016 amfAR All Rights Reserved